<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00440674</url>
  </required_header>
  <id_info>
    <org_study_id>The DECIDE Trial: CP-05</org_study_id>
    <nct_id>NCT00440674</nct_id>
  </id_info>
  <brief_title>Prospective, Multi-Center, Random. Study of CoStar Paclitaxel-Eluting Coronary Stent(Direct Stenting vs. Pre-Dilatation)</brief_title>
  <acronym>DECIDE</acronym>
  <official_title>The DECIDE Trial: Prospective, Multi-center, Randomized Study to Evaluate the CoStar Paclitaxel-Eluting Coronary Stent System Using a Direct Stenting Technique Compared to Conventional Stenting With Pre-dilatation Strategy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Conor Medsystems</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Conor Medsystems</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety and effectiveness of a direct&#xD;
      stenting technique compared to conventional stenting with pre-dilatation strategy using the&#xD;
      CoStar Paclitaxel-eluting coronary stent system for the treatment of a single de novo lesion&#xD;
      in a native coronary artery ≤ 25 mm long in a native coronary artery 2.5-3.5 mm diameter.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, multi-center, randomized (1:1), open-label study to evaluate direct stenting&#xD;
      compared to conventional stenting with pre-dilatation strategy in treatment of a single de&#xD;
      novo Lesion of a single native coronary artery in patients undergoing elective percutaneous&#xD;
      coronary intervention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adjudicated MACE at 30 days</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Primary &amp; second. device success, Lesion and Procedure success, Adjudicated MACE 8, 9, 12, 24 mos post-proc; Binary restenosis, MLD, Clin. driven TLR 8 mos post-proc; Clinic. driven TVR 8 mos post-proc; Overall TVR/TLR 8 mos post-proc; Stent thrombosis</measure>
    <time_frame>8, 9, 12, 24 mos post-proc</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Direct stenting technique</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conventional stenting with pre-dilatation strategy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CoStar Paclitaxel-eluting coronary stent system</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eligible for percutaneous coronary intervention&#xD;
&#xD;
          -  Documented stable or unstable angina pectoris or with documented ischemia, or with&#xD;
             documented silent ischemia&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) ≥25% documented within the last 6 weeks&#xD;
&#xD;
          -  Acceptable candidate for coronary artery bypass graft surgery&#xD;
&#xD;
          -  Single target vessel / single target lesion to be treated&#xD;
&#xD;
          -  Target lesion may be composed of multiple lesions but must be completely coverable by&#xD;
             one (1) study stent&#xD;
&#xD;
          -  Cumulative target lesion length per vessel is ≤ 25 mm&#xD;
&#xD;
          -  RVD of 2.5-3.5 mm&#xD;
&#xD;
          -  Target lesion diameter stenosis ≥ 50% and &lt; 100%&#xD;
&#xD;
          -  Target vessel has not undergone prior revascularization within the preceding 6 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known sensitivity to cobalt chromium, Paclitaxel or PLGA&#xD;
&#xD;
          -  Acute MI within 72 hours prior to the index procedure as defined by the presence of a&#xD;
             new pathologic Q-wave, or a creatine kinase (CK) level of &gt; 2x the laboratory upper&#xD;
             limits of normal and elevated MB&#xD;
&#xD;
          -  The patient is in cardiogenic shock&#xD;
&#xD;
          -  Cerebrovascular Accident (CVA) within the past 6 months&#xD;
&#xD;
          -  Acute or chronic renal dysfunction (creatinine &gt; 2.0 mg/dL or &gt; 150 µmol/L)/&#xD;
&#xD;
          -  Contraindication to ASA or to Clopidogrel&#xD;
&#xD;
          -  Thrombocytopenia (platelet count &lt;100,000/mm3)&#xD;
&#xD;
          -  Active gastrointestinal (GI) bleeding within the past three months&#xD;
&#xD;
          -  Any prior true anaphylactic reaction to contrast agents&#xD;
&#xD;
          -  Patient is currently taking Colchicine&#xD;
&#xD;
          -  Patient is currently, or has been treated with Paclitaxel (systemic) within12 months&#xD;
             of the index procedure&#xD;
&#xD;
          -  Comorbid condition(s) that could limit the patient's ability to participate in the&#xD;
             study, compliance with follow-up requirements or impact the scientific integrity of&#xD;
             the study&#xD;
&#xD;
          -  Left main coronary artery disease (stenosis &gt;50%), whether protected or unprotected.&#xD;
&#xD;
          -  Target lesion involves a bifurcation with a diseased (&gt;50% stenotic) branch vessel&#xD;
             &gt;2.0 mm in diameter that requires intervention.&#xD;
&#xD;
          -  Target lesion is totally occluded Thrombolysis In MI (TIMI flow ≤1).&#xD;
&#xD;
          -  The target vessel has had prior drug-eluting stent placement to vessel segment (or&#xD;
             branch) proximal to intended target lesion site.&#xD;
&#xD;
          -  Angiographic restenosis of any segment of the target vessel that has undergone prior&#xD;
             PCI.&#xD;
&#xD;
          -  Angiographic evidence of atherosclerotic disease with &gt;50% diameter stenosis (by&#xD;
             visual estimate) proximal or distal to the target lesion (applies to the major&#xD;
             epicardial portion of the target vessel and contiguous vessel segment if the target&#xD;
             lesion is located in a branch vessel)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joachim Schofer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitäres Herz-und Gefäßzentrum Hamburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitäres Herz-und Gefäßzentrum Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>D-22527</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <study_first_submitted>February 23, 2007</study_first_submitted>
  <study_first_submitted_qc>February 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2007</study_first_posted>
  <last_update_submitted>October 29, 2009</last_update_submitted>
  <last_update_submitted_qc>October 29, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2009</last_update_posted>
  <responsible_party>
    <name_title>Joachim Schofer, Principal Investigator</name_title>
    <organization>Universitäres Herz-und Gefäßzentrum Hamburg</organization>
  </responsible_party>
  <keyword>Direct Stenting</keyword>
  <keyword>Angioplasty</keyword>
  <keyword>Pre-dilatation</keyword>
  <keyword>Drug-eluting stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Dilatation, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

